TY - JOUR T1 - FDA-approved drug screening identified micafungin as an antiviral agent against bat-borne emerging zoonotic Pteropine orthoreovirus JF - bioRxiv DO - 10.1101/2022.09.21.508823 SP - 2022.09.21.508823 AU - Tetsufumi Katta AU - Ayato Sato AU - Naoya Kadofusa AU - Tomoki Ishibashi AU - Hiroshi Shimoda AU - Atsuo Iida AU - Eiichi Hondo Y1 - 2022/01/01 UR - http://biorxiv.org/content/early/2022/09/22/2022.09.21.508823.abstract N2 - Bat-borne emerging zoonotic viruses cause major outbreaks, such as the Ebola virus, Nipah virus, severe acute respiratory syndrome (SARS) coronavirus, and SARS-CoV-2. Pteropine orthoreovirus (PRV), which spillover event occurred from fruit bats to humans, causes respiratory syndrome in humans widely in South East Asia. Repurposing approved drugs against PRV is a critical tool to confront future PRV pandemics. We screened 2,943 compounds in an FDA-approved drug library and identified eight hit compounds that reduce viral cytopathic effects on cultured Vero cells. Real-time quantitative PCR analysis revealed that six of eight hit compounds significantly inhibited PRV replication. Among them, micafungin used clinically as an antifungal drug, displayed a prominent antiviral effect on PRV.HighlightsA library of 2,943 FDA-approved drugs was screened to find potential antiviral drugs of Pteropine orthoreovirus.Six hit compounds dramatically inhibited viral replication in vitro.Micafungin possessed antiviral activity to multiple strains of PRV.Competing Interest StatementThe authors have declared no competing interest. ER -